Other News To Note
Wednesday, November 30, 2011
Civitas Therapeutics Inc., of Chelsea, Mass., received a grant from The Michael J. Fox Foundation for Parkinson's Research to support clinical development of its lead Parkinson's disease candidate CVT-301, an inhaled formulation of levodopa (L-dopa). Privately held Civitas did not disclose the funding amount, but said it would support studies of CVT-301 through proof of concept, expected to conclude by year-end 2012.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.